GOVX GeoVax Labs, Inc.
$0.20▲ +3.50%
Healthcare
Other
Volume 185.2K
Avg Volume (10D) 277.6K
Key Metrics & Fundamentals
Market Cap
$2.03M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.19 - 15.18
% vs 50 MA
-50.37%
% vs 200 MA
-84.58%
RSI-14
20.9
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.74
Free Cash Flow
-$3.66M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$4.43M
COGS
–
Operating Exp
$4.44M
Operating Income
-$4.44M
EBIT
-$4.44M
Pretax Income
-$4.43M
Net Income
-$4.43M
EPS (Diluted)
-0.97
Price & Volume History
Loading chart…
Recent News
Update - GeoVax Enters Into $1 Million Revolving Loan Agreement
NewMediaWire · Oct 27, 2026 8:30 AM ET
GeoVax Enters Into $1 Million Revolving Loan Agreement
NewMediaWire · Oct 26, 2026 5:27 PM ET
GeoVax to Highlight Next-Generation MVA Vaccine and Manufacturing Advances at World Vaccine Congress Europe 2026
NewMediaWire · Oct 6, 2026 8:37 AM ET
GeoVax Highlights Likely Sustained Clade Ib Mpox Transmission in the United States
NewMediaWire · Sep 29, 2026 8:37 AM ET
GeoVax Next-Generation MVA Vaccine Demonstrates Durable Single-Dose Protection in Preclinical Models
NewMediaWire · Sep 21, 2026 8:37 AM ET
GeoVax Confirms Bundibugyo Ebola Vaccine Construct
NewMediaWire · Sep 16, 2026 8:37 AM ET
GeoVax and CEPI Enter Agreement to Utilize CEPI Centralised Laboratory Network to Support GEO-MVA Phase 3 Trial
NewMediaWire · Sep 14, 2026 8:37 AM ET
GeoVax Provides Nasdaq Listing Update and Reaffirms Focus on Advancing Strategic Priorities
NewMediaWire · Sep 10, 2026 8:37 AM ET
GeoVax Welcomes Launch of Global Mpox Vaccine Stockpile, Highlights GEO-MVA Readiness to Support Diversified Global Supply
NewMediaWire · Sep 9, 2026 9:00 AM ET
GeoVax Announces a Warrant Inducement Transaction
NewMediaWire · Aug 26, 2026 8:30 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2025
See GOVX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.